PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient popul...

Full description

Bibliographic Details
Main Authors: Rosa A. van Amerongen, Sander Tuit, Anne K. Wouters, Marian van de Meent, Sterre L. Siekman, Miranda H. Meeuwsen, Tassilo L. A. Wachsmann, Dennis F. G. Remst, Renate S. Hagedoorn, Dirk M. van der Steen, Arnoud H. de Ru, Els M. E. Verdegaal, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
ovarian cancer
PRAME
CTCFL
CLDN6
TCR gene transfer
T-cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121973/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121973/full

Similar Items